Viruses can have a devastating effect despite their small genomes. All RNA viruses encode proteins that are essential for structural components and replication, and most encode proteins that function to circumvent host antiviral responses1–3. This limited number of proteins is sufficient to ensure the entry, replication and subsequent spread of the virus. However, viruses do not self-propagate and depend on various host-cell functions to complete their life cycle. The processes of viral entry, the triggering and regulation of the host antiviral response and subsequent viral replication together result in an intricate series of interactions between virus and host. Much can be learnt about the nature and complexities of these interactions by global profiling of the transcriptional changes in host cells that occur during viral infection (BOX 1).

In this Review, we discuss how functional genomic and systems-biology approaches are contributing to our understanding of interactions between RNA viruses and the host, of viral pathogenesis and of host immunity to infection. Rather than providing a comprehensive literature review, we present examples of how these approaches are providing insight into the interaction of viruses with innate immune defence mechanisms, the evaluation of therapeutics that target these pathways and the crucial balance between protective immune responses and immunopathology. In addition, we describe how genomic approaches are being applied to vaccine evaluation and design, and how these approaches can be combined with other high-throughput technologies to provide an improved and integrated systems-biology view of virus infection.

Although genomic approaches are being used to study a wide variety of viruses, we highlight the current literature through discussion of a select few. Among these is influenza virus, for which the looming threat of a new pandemic and concerns regarding therapeutic and vaccine preparedness have stimulated exciting new research efforts. We also review findings relating to hepatitis C virus (HCV) infection, for which genomic analyses are being used to shed light on the response of patients to treatment with type I interferons (IFNs) and the relationship between HCV replication and liver disease. In addition, we highlight studies of West Nile virus, severe acute respiratory syndrome-associated coronavirus (SARS-CoV) and Ebola virus, all of which have revealed previously undescribed strategies used by these viruses to regulate innate immunity. Finally, we discuss how genomic approaches are being applied to vaccine evaluation and how genomics is being combined with other high-throughput approaches to provide a systems-biology view of virus–host interactions.

**Viruses and innate immunity**
A variety of cellular signalling networks have evolved in host cells to detect and respond to viral infection. One area in which genomics-based analyses are being put to
Functional genomics

Genomics is broadly defined as the study of genomes. The term was first adopted nearly 20 years ago to describe the emerging discipline of using nucleotide sequencing, gene mapping and computational biology to define the structure and organization of a genome. As ever increasing amounts of nucleotide sequence information have become available, the focus of genomics has expanded to include gene function. The Human Genome Project was a driving force in advancing both structural and functional genomics, and the nucleotide sequence information generated by this project has fuelled tremendous advances in our understanding of human health and disease. One way in which this has occurred is through the convergence of comprehensive genome sequence information with advances in high-throughput technology.

Today, the standard technology in functional genomics is the oligonucleotide microarray. Several alternative platforms are available, with the most common being microarrays for which thousands of oligonucleotide ‘probes’, each corresponding to an mRNA transcript, are synthesized in situ directly on a glass slide. Such microarrays enable researchers to simultaneously measure the expression of virtually all genes in a genome. For ‘target’ preparation, mRNA is extracted from experimental samples and labelled with fluorescent dyes by reverse transcription. The labelled target is then hybridized with the microarray, and the fluorescence of the features is determined using an array scanner. Following image analysis, the data are subjected to a variety of bioinformatic processes to identify statistically significant changes in gene expression between samples. Because each comparison yields tens of thousands of data points, mining the data for biological meaning is a formidable challenge. A variety of sophisticated commercial and open-source analysis tools are therefore used to find relationships between differentially expressed genes, to identify networks or signalling pathways that are activated or repressed and to compare gene-expression profiles between experimental samples.

Viral triggering of innate immunity. Mammalian cells have specialized proteins that are responsible for the recognition of virus infection, and other proteins that elicit responses to combat the invading virus. The antiviral response is triggered when host pathogen-recognition receptors (PRRs) are engaged by pathogen-associated molecular patterns (PAMPs) in viral proteins and nucleic acids (reviewed in Refs 4,5). PRRs that function in virus recognition include the cytosolic double-stranded RNA helicases retinoic-acid-inducible gene I (RIG-I) and MDA5 (melanoma differentiation-associated gene 5) and certain Toll-like receptors (TLRs) that are present on the cell surface or in endosomal membranes. After binding to viral PAMPs, PRRs initiate intracellular signalling cascades that result in the activation of transcription factors, including IFN-regulatory factors (IRFs) and nuclear factor-κB (NF-κB). These transcription factors in turn regulate the expression of hundreds of genes, such as IFNs and IFN-stimulated genes (ISGs) and pro-inflammatory cytokines and chemokines that are involved in the orchestration of the adaptive immune response (Fig. 1).

One way in which gene-expression profiling has been used to examine this aspect of the antiviral response is through the use of mouse embryonic fibroblasts deficient in RIG-I or MDA5. A recent study demonstrated that West Nile virus infection of wild-type cells led to the induction of IFN3 target genes and ISGs, including several subtypes of IFNζ (Ref. 8). This was followed by a second phase of IFN-dependent antiviral gene expression that occurred at a later stage of infection. In contrast, cells lacking RIG-I had delayed or inhibited initial and secondary gene-expression responses to the virus, indicating that RIG-I has an essential but not exclusive role in initiating innate immune responses to West Nile virus (Fig. 2). The additional deletion of MDA5 in these cells was found to further block their ability to respond to infection, indicating that the host immune response to West Nile virus also involves MDA5. This is a noteworthy finding, as previous studies suggested that RIG-I and MDA5 recognized a specific subset of viruses, rather than acting cooperatively as found in the response to West Nile virus.

The role of RIG-I in the response to influenza virus infection has also been assessed. Similar to West Nile virus, genomic analysis of influenza virus-infected wild-type and RIG-I-deficient mouse embryonic fibroblasts revealed that RIG-I is necessary for the type I IFN response to this virus (Fig. 2). In RIG-I-deficient cells, influenza virus fails to elicit the expression of IFNβ and of many ISGs, including key antiviral mediators such as IFNβ, STAT1 (signal transducer and activator of transcription 1), IFIT1 (IFN-induced protein with tetratricopeptide repeats 1; also known as ISG56) and ISG54 (also known as IFIT2). This study also showed that, unlike during infection with West Nile virus, MDA5 does not function as a secondary mediator of the response to infection with influenza virus. Important next steps in these studies will be to compare the profiles of genes induced by each of these viruses — and to determine whether some genes are specific for RIG-I or MDA5 signalling — and to begin to define the involvement of these genes in innate immunity. Although this biological validation process will be necessary to follow-up genomic analyses, few studies so far have included such experiments.

Functional genomic analyses have also been helpful in elucidating the complex transcriptional events triggered following TLR signalling. TLRs are expressed by various immune cells, including macrophages, dendritic cells and lymphocytes, and a subset of these receptors are involved in innate recognition. So far, genomic studies have largely focused on the analysis of macrophages treated with TLR ligands, such as lipopolysaccharide (LPS; a component of the cell wall of Gram-negative bacteria) or polyinosinic–polycytidylic acid (a synthetic mimic of viral double-stranded RNA, dsRNA).

To obtain a comprehensive view of the transcriptional programmes that are induced by TLR activation, Elkon et al. used a computational approach to analyse gene-expression data sets derived from four studies in which human or mouse macrophages were stimulated with pathogen-mimetic agents that engage various TLRs. This analysis identified one transcriptional profile that is universally activated by all TLRs and a second profile that is specific to both TLR3 (which specializes in the recognition of viral dsRNA) and TLR4 (which recognizes...
The image contains a diagram illustrating the stimulation of interferon-stimulated gene expression and the initiation of antiviral activity. Pathogen-associated molecular patterns (PAMPs) in viral proteins and nucleic acids are recognized by cellular pathogen-recognition receptors (PRRs) that include RIG-I (retinoic-acid-inducible gene I), MDA5 (melanoma differentiation-associated gene 5) and certain Toll-like receptors (TLRs). PRR–PAMP interactions trigger signalling cascades that result in the activation of transcription factors, including interferon (IFN)-regulatory factor 3 (IRF3) and nuclear factor-κB (NF-κB), which induce the production of type I IFNs, IFN-stimulated genes (ISGs) and pro-inflammatory cytokines and chemokines. The specific process differs between antigen-presenting cells, in which both the TLR pathway and the RIG-I or MDA5 pathway are operative, and other cell types, in which only the RIG-I or MDA5 pathway is present. Activation of PRR signalling induces an antiviral state in all cell types, and in antigen-presenting cells it can also induce the production of pro-inflammatory cytokines and chemokines. This normally results in an innate antiviral response that controls infection until it is resolved by the adaptive immune response. However, some viruses, such as the 1918 pandemic influenza virus, elicit an aberrant or disproportional response that results in immunopathology. Alternatively, viruses that suppress the type I IFN response can subvert the mechanisms of innate surveillance and diminish the potential adaptive immune response, resulting in a chronic infection. For vaccine strategies, the best induction of a broad adaptive immune response might require some degree of type I IFN response in the initial stages of infection. DCs, dendritic cells; dsRNA, double-stranded RNA; IFNAR, IFNα receptor; IL, interleukin; IPS1, IFNB-promoter stimulator 1; OAS, 2′,5′-oligoadenylate synthetase; PKR, protein kinase R; ssRNA, single-stranded RNA; STAT, signal transducer and activator of transcription; TAP1, transporter associated with antigen presentation 1; TNF, tumour-necrosis factor.
activated in both the universal and TLR3- and TLR4-mediated responses. Although these studies have provided considerable information regarding the genes activated downstream of TLR activation, it will be advantageous to extend genomic analyses in the context of viral infection using cells lacking the expression of specific TLRs.

Viral regulation of innate immunity. The ability of a virus to establish an infection depends, at least to some extent, on its ability to block the host innate immune response or to modulate the activity of antiviral effector proteins. HCV is one example of a virus that has devised a means to block the initial triggering of the host innate immune response. Several studies have shown that the HCV NS3–NS4A serine protease blocks the TLR3-dependent activation of IRF3 (REFS 17,19). This is achieved by NS3–NS4A-mediated cleavage of TRIF (Toll/interleukin-1 receptor-domain-containing adaptor protein inducing IFNβ), an adaptor protein that links TLR3 to kinases that are responsible for activating IRF3 and NF-κB17,19. HCV also inhibits the ability of RIG-I to activate IRF3 (REFS 15,16,18,20), which is achieved through NS3–NS4A-mediated cleavage of IPS1 (IFNB promoter stimulator 1; also known as VIS, CARDIF, MAVS), a recently identified RIG-I adaptor protein21–25.

In light of these findings, it is both perplexing and paradoxical that virtually all gene-expression profiling carried out using HCV-infected tissue shows the induction of ISG expression, including IRF3 target genes26–30. The induction of ISG expression is observed in liver tissue from HCV-infected patients30,32,37 and during the initial host response in acutely infected chimpanzees26,28, and is a major part of the transcriptional response to HCV infection in the chimeric SCID-Alb/uPA mouse model31. This poses an interesting question about the source of both type I IFNs and ISG expression. It is possible that ISGs are mainly expressed in uninfected hepatocytes and are induced in response to exogenous type I IFN released from adjacent HCV-infected cells. Alternatively, it has been suggested that T cells and plasmacytid dendritic cells that infiltrate the liver are a possible source of hepatic type I IFNs. Although this is possible, it is relevant to note that HCV infection in the SCID-Alb/uPA mouse model is also associated with the induction of hepatic ISG expression in the absence of these immune cell types39.

Other genomic studies have revealed examples of highly virulent viruses that are relatively successful at inhibiting ISG expression. Perhaps the best example is a characterization of the host transcriptional response of human liver cells infected with filoviruses38. This study demonstrated the marked suppression of genes in key innate antiviral pathways, including those mediated by IRF3. Interestingly, this study also suggested a correlation between the antagonism of the type I IFN response and filovirus virulence. Highly virulent viruses, such as Zaire Ebola virus and Marburg virus, inhibit the expression of most ISGs that are induced in uninfected IFN-treated cells. By contrast, the relatively non-pathogenic Reston Ebola virus is less inhibitory and induces the expression of more than 20% of these genes. The suppression of the type I IFN response by the pathogenic viruses is associated with more rapid viral spread and higher rate of viral replication than that observed during Reston Ebola virus infection.

A comparable trend was seen in a study evaluating the host transcriptional response and inflammation in the brains of mice infected with rabies virus33. This study revealed that infection with an attenuated virus results in both inflammation and the induction of expression of key ISGs. However, these events are either absent or diminished during infection with a highly pathogenic rabies virus. On the basis of results with filoviruses, it would follow that attenuation of the type I IFN response would be associated with higher viral replication and spread in the case of pathogenic infection with rabies virus; however, this was not measured in the study. Similarly, infection with highly virulent pseudorabies virus suppressed the induction of a subset of ISGs, even in type I IFN-treated cells34. Together, these data suggest that the virulence of acute, highly pathogenic viruses is at least partially related to their ability to suppress the host antiviral response, which seems to allow higher levels of viral replication.

Figure 2 | Virus-induced gene-expression profiles in RIG-I-deficient cells. Genomic analyses using cells that lack RIG-I (retinoic-acid-inducible gene I) show the requirement for this pattern-recognition receptor in the induction of interferon-regulatory factor 3 (IRF3) target genes and interferon-stimulated genes (ISGs) by West Nile virus and influenza virus. a | The infection of RIG-I-deficient cells by West Nile virus results in the delay and partial inhibition of ISG expression. Deletion of MDA5 (melanoma differentiation-associated gene 5) further blocks the response to infection (not shown), indicating that the response to West Nile virus also involves MDA5. b | By contrast, the infection of RIG-I-deficient cells by influenza virus results in a complete inhibition of ISG expression that is not further blocked by the absence of MDA5, suggesting that MDA5 does not mediate influenza virus-induced gene-expression changes. PAMPs, pathogen-associated molecular patterns. Images generated from data in REFs 8,10.

Chimeric SCID-Alb/uPA mouse model
A chimeric mouse model of severe combined immunodeficient (SCID) mice that contain a urokinase plasminogen activator transgene driven by an albumin promoter (Alb/uPA) These mice can be transplanted with human hepatocytes to generate chimeric mouse–human livers, providing the only small-animal infection model for hepatitis C virus infection.
Suppression of innate immunity and persistent infection. Evidence discussed in this Review suggests that suppression of elements of the innate immune response enables extensive viral replication and increased pathogenesis. Does the converse hold true for a virus such as HCV, which typically establishes a persistent infection characterized by mild (or slowly progressing) disease? Some evidence suggests that this might be the case; for example, studies using the chimeric SCID-Ab/uPA mouse model indicate that an attenuated type I IFN response is associated with higher levels of intrahepatic HCV replication together with a greater induction of lipid metabolism and oxidative-stress genes, which have the potential to cause cytopathic effects.

Similarly, gene-expression profiling of serial liver biopsies obtained from patients that had received an HCV-infected liver transplant shows that rapid progression of fibrosis following transplantation is associated with the suppression of genes involved in the type I IFN response, antigen presentation and the cytotoxic T-cell response. Although in these studies the apparent defect in the host antiviral response is probably related to host genetics rather than viral factors, the concept that a defective innate immune response correlates with enhanced pathogenesis is still evident. It is possible that the selective pressures on persistent viruses never resulted in a need for a complete subversion of host antiviral responses, so such viruses use these responses to limit their replication to a level that does not significantly affect the normal functions of the host cell. Conversely, acute viruses, such as filoviruses, highly pathogenic influenza virus and rabies virus, seem to have evolved to antagonize these responses following cell entry to allow immediate, high levels of replication, which subsequently facilitate virus spread and transmission.

Innate immunity as a target for therapeutic intervention. Given the importance of the innate immune response in regulating virus infection, there is considerable interest in enhancing or modulating this response for therapeutic benefit. One role for genomics in this area is assisting in the evaluation of type I IFN treatment of HCV infection. Combination therapy with IFNα and the antiviral drug ribavirin results in virus clearance in only ~50% of individuals infected with HCV genotype 1 and ~80% of individuals infected with HCV genotypes 2 or 3 (REFS 41–44). As IFNα is the only approved treatment for chronic HCV, there is strong interest in improving this therapy, in understanding the molecular mechanisms that underlie treatment failure and in identifying markers to accurately predict a patient’s response to treatment (that is, responders or non-responders).

Several groups that have used transcriptional profiling of patient hepatic tissue to address these issues have found that higher levels of expression of ISGs before treatment are associated with treatment failure. For example, Chen et al. carried out microarray experiments on pretreatment liver tissue obtained from a cohort of 31 patients with chronic HCV infection who subsequently underwent IFNα and ribavirin therapy. This analysis identified a set of 18 genes, many of which are known ISGs; in general these genes were more highly induced in the livers of patients that did not respond to therapy. Although the authors suggest that this set of genes could therefore be used to predict the response to therapy, it remains to be determined whether they can be used to accurately predict the response in other patient cohorts. Similarly, Feld et al. showed that non-responders have significantly higher intrahepatic pretreatment expression levels of ISGs than patients who respond to type I IFN therapy. Although these studies are intriguing, it is still unclear whether there is a causal relationship between higher pretreatment levels of ISGs and therapy failure. Other factors, such as viral quasispecies diversity, may also be important.

Owing to the technical and ethical issues of obtaining sufficient liver material for gene-expression studies, investigators have also used peripheral-blood mononuclear cells (PBMCs) to evaluate the response to treatment. An example is ViralHepC, a multicentre study designed to define the differences in response rates among Caucasian and African Americans and to identify host and viral parameters associated with a lack of response to treatment. Overall, this study showed that, during the first 28 days of treatment, a lower level of induction of known ISGs is associated with nonresponsiveness to type I IFN treatment. However, in many cases, these differences are not strikingly dissimilar between responders and non-responders. The implication of such minor differences with respect to antiviral function is uncertain and the feasibility of using them for predicting a patient’s response is questionable. In addition, analyses using PBMCs should be interpreted with caution, as a recent study showed that the transcriptional response to type I IFN treatment is significantly different in the blood and the liver of HCV-infected chimpanzees, presumably owing to the absence of HCV replication in PBMCs. Although it has not yet been evaluated, this will almost certainly hold true for humans as well.

An alternative mechanism of a failed response to type I IFN treatment could involve the induction of genes associated with IFN inhibitory pathways. Walsh et al. found significantly increased intrahepatic expression of the gene encoding suppressor of cytokine signalling 3 (SOCS3) in patients who did not respond to type I IFN treatment. Enhanced intrahepatic SOCS3 expression is also thought to contribute to the non-responsiveness of HCV-infected chimpanzees to type I IFN therapy. However, a separate evaluation of 21 patients for intrahepatic SOCS3 mRNA expression before antiviral therapy actually found higher levels of expression in those patients who went on to respond successfully to type I IFN treatment. Therefore, the relationship between treatment failure and induction of type I IFN inhibitory pathways is currently less clear than that between higher pretreatment levels of expression of ISGs and treatment failure.

Innate immune protection versus immunopathology. There are still surprisingly few answers to the fundamental question of how virus infection results in disease pathology. Although the mechanisms are certain to be different for each virus, a common theme is that there is
a crucial balance between protective immune responses and immunopathology\textsuperscript{2,37}. Although the innate immune response is designed to target and eliminate invading pathogens, genomic analyses have indicated that some viruses, such as the highly virulent influenza virus that was responsible for the 1918 pandemic, elicit aberrant or disproportional innate immune responses that may also harm the host.

The 1918 influenza virus pandemic (known as the Spanish Flu) killed as many as 50 million people worldwide\textsuperscript{54}, and several studies have begun to provide clues to what made this virus so deadly (reviewed in REFS 55–57). Although genomic analyses have previously been carried out using engineered viruses containing one or more genes from the 1918 pandemic virus\textsuperscript{56,59}, a major advance in the ability to study this virus came from its reconstruction based on nucleotide sequence information\textsuperscript{60}. Genomic analyses of lung or bronchial tissue derived from mice or macaques that were infected with the reconstructed 1918 virus indicate how the beneficial role of the innate immune response can be tipped towards immunopathology.

Mice infected with the reconstituted 1918 influenza virus show severe pulmonary pathology and an increased and accelerated transcriptional activation of immune-response genes\textsuperscript{61}. This includes a marked activation of genes associated with pro-inflammatory and cell-death pathways by 24 hours after infection (FIG. 3), which remain unabated until the death of the animals. This response is in contrast to the less dramatic and delayed host immune responses (and less severe disease pathology) in mice that were infected with influenza viruses containing only subsets of genes from the 1918 virus, including the haemagglutinin (HA) and non-structural protein (NS) genes, or the HA, neuraminidase (NA), matrix (M) and nucleoprotein (NP) genes. These findings suggest that enhanced pro-inflammatory and cell-death responses can contribute to severe immunopathology.

An additional study that evaluated the host response to the 1918 influenza virus using a cynomologus macaque (Macaca fascicularis) infection model produced similar results\textsuperscript{62}. In macaques, the 1918 virus replicates to high levels and spreads rapidly throughout the respiratory tract of infected animals, causing severe lung damage and the massive infiltration of immune cells throughout the course of infection. Functional genomic analyses of bronchial tissue revealed that the 1918 virus triggers the aberrantly high and sustained expression of numerous genes involved in the innate immune response, including pro-inflammatory cytokines and chemokines. Although the timing of the response is somewhat different, the increased and sustained host response in macaques that were infected with the 1918 virus is similar to that observed in mice.

These studies reveal similarities and differences in the host response to contemporary and 1918 pandemic influenza virus infection. First, contemporary and 1918 viruses each trigger an innate immune response that includes the expression of NF-κB and IRF3 target genes. However, the gene-expression response triggered by the contemporary virus is moderate and transient and accompanied by only mild clinical symptoms. The gene-expression response to the 1918 virus is aberrantly high and sustained and may contribute to the severe clinical symptoms, including alveolitis, haemorrhage and neutrophil infiltration, that are observed in animals infected with this virus. This disproportional innate immune response and resulting immunopathology could also be the cause of the increased severity of symptoms observed in people during the 1918 pandemic. Images reproduced, with permission, from Nature REF. 61 © 2006 Macmillan Publishers Ltd. All rights reserved.
The enhanced pathogenicity of the 1918 and H5N1 influenza viruses might be attributed to distinct components of their genomes. Although much emphasis has been placed on the NS1 protein of the 1918 virus acting as an inhibitor of the type I IFN response, recent evidence suggests that the viral proteins PB1 (a polymerase), HA and NA contribute to its pathogenicity. Likewise, the polymerases of H5N1 viruses have been linked to increased viral pathogenesis, suggesting that the increased pathogenesis of these viruses may be related to their replicative fitness.

Another respiratory virus, SARS-CoV, has emerged recently and has caused great concern among the public health and research communities. It has been suggested that disease pathology associated with SARS-CoV is caused by a disproportional immune response, illustrated by increased levels of pro-inflammatory cytokines and chemokines. Studies carried out in our laboratory have combined the use of functional genomics with a cynomolgus macaque infection model to study the host response to this virus. We observed that SARS-CoV-infected macaques show a strong increase in the expression of innate immune response genes early after infection and that this response wanes after 4 days. Conversely, genes that are induced later in infection tend to be involved in the cell cycle and in cell repair. None of the animals used in this study succumbed to infection, and SARS-CoV-induced pathology in these macaques resembled the pathological changes seen in the majority of human patients with SARS who recover from the disease. Unlike the findings of the 1918 pandemic influenza virus study, these data suggest that early immune responses to SARS-CoV infection are productive and enable the host to properly fight the virus, allowing a return to cellular homeostasis. However, in the 10% of human infections in which SARS-CoV infection is fatal (mostly in the elderly), it is possible that the timing or magnitude of the response results in immunopathology. Studies using aged macaques might help to address this possibility.

Viruses such as SARS-CoV, H5N1 influenza virus and 1918 influenza virus are all zoonotic infections, in which a virus that was adapted to another host was transferred to humans. Because the type I IFN response is somewhat different in different hosts, it is possible that these viruses, which have adapted to their normal animal hosts, elicit an aberrant response when infecting a human host in which adaptation has not occurred, resulting in immunopathology. This possibility also raises the question of how appropriate the various animal infection models (such as mice and macaques) are for the understanding of human pathogenesis. As reviewed elsewhere, there are both advantages and disadvantages associated with different animal models, and it is important to keep in mind that responses observed using an animal model may not always accurately reflect the response in humans.

Genomics in vaccine evaluation and design
Genomic information and high-throughput technologies are beginning to have an impact on the field of vaccine development, but the main focus has been directed towards identifying important conserved features of pathogens that could serve as immunogens and characterizing host genotypes associated with strong protective responses. In recent years, it has become evident that the type I IFN response has a significant role in the development of the adaptive immune response. This commences with the influence of type I IFNs on the activation, maturation and migration of dendritic cells. The development of the antibody response is also enhanced by type I IFNs through the direct effect of IFN on B cells and on the priming or function of CD4+ T helper cells. There is now also evidence that type I IFNs act directly on CD8+ T cells to promote clonal expansion and indirectly by stimulating cross-priming by antigen-presenting cells that have engulfed infected cells to acquire antigen. So, viruses that suppress the type I IFN response not only subvert the mechanisms of innate surveillance, but also diminish the potential adaptive immune response that could mediate viral clearance or establish a quiescent, non-pathogenic state. For vaccine strategies, the implication is then that the best induction of a broad adaptive immune response will require some degree of type I IFN response in the initial stages.

Box 2 | Immunomics

Just as DNA microarray technology spurred the development of functional genomics, the development of immunomic microarray technology is driving the emerging field of functional immunomics. The goal of immunomics is to provide a detailed understanding of host immunological responses to foreign antigens through the use of high-throughput technologies and computational methods. The technologies that are central to this effort include antibody microarrays (consisting of antibodies as probes and antigens as targets), peptide microarrays (consisting of antigen peptides as probes and serum antibodies as targets) and more recently peptide–MHC microarrays (consisting of recombinant peptide–MHC complexes and co-stimulatory molecules as probes and populations of T cells as targets).

Antibody microarrays are used to measure the concentration of specific antigens (such as cancer antigens), whereas peptide–MHC microarrays can map MHC-restricted T-cell epitopes which are involved in helper and regulatory functions of the immune system. Peptide microarrays are used in various applications, including B-cell epitope mapping and detection and diagnostic assays. Peptide microarrays are also being used in vaccine studies for mapping epitopes associated with effective immune responses and for testing the ability of experimental vaccines to generate specific antibody responses against those epitopes upon immunization and challenge. Studies of immune responses that are associated with different clinical outcomes, such as those of patients who are HIV positive and who rapidly progress to AIDS and those of infected long-term survivors, can also provide direction for the development of vaccines. It is probable that immunomics will become an increasingly integral part of a systems-biology approach to vaccine development and of obtaining a better understanding of host immunity to virus infection.
Animal models. We have used functional genomics to evaluate a live influenza virus vaccine in a macaque model, in which attenuation of the virus was accomplished by truncation of the gene encoding NS178. This modification eliminates or reduces the ability of the NS1 protein to antagonize type I IFN production79 and, in mouse and swine models, such attenuated live viruses are immunogenic and protective80,81. Gene-expression profiling of tracheal and bronchial epithelial cells from macaques immunized with the NS1-truncated virus show clear evidence of a robust type I IFN response. Compared with immunization with a traditional killed-virus vaccine, the attenuated live-virus-vaccine group had higher antibody titres before and after challenge and a broader range of influenza virus-specific T-cell responses. Following challenge with infective virus, the protection afforded by the attenuated live-virus vaccine was evident by the limited viral replication and minor pathology observed in treated animals. In addition, gene-expression profiles of lung tissue from animals that received the attenuated live-virus vaccine show less upregulation of innate and pro-inflammatory response genes compared with animals immunized with the killed-virus vaccine or untreated animals. At the same time, the transcriptional profiles for the attenuated live-virus-vaccine animals showed a stronger induction of genes that are associated with B-cell and T-cell responses.

The general picture overall is that the truncated-NS1-containing influenza virus vaccine undergoes minimal replication but induces sufficient type I IFNs to galvanize the adaptive immune response, leaving the host in a state of adaptive preparedness after just one immunization. The early induction of type I IFNs in response to the truncated-NS1-containing vaccine might be especially important in the local B-cell response that is crucial for viral clearance. A relevant observation in this regard is that early stimulation of the respiratory-tract B cells (within 48 hours of influenza virus infection) was shown to be strongly driven by virus-induced type I IFNs82,83.

Human studies. At present, there are only limited examples in which gene-expression profiling applied to vaccine design supports a picture consistent with that described above for the influenza virus model. The standards for prevention of measles and yellow fever are immunizations with attenuated live-virus vaccines. To assess the impact of infection on primary target cells, gene-expression profiling was carried out in tissue-culture systems comparing wild-type and vaccine strains. For both measles and yellow fever, it was clear that the attenuated vaccine strains led to a greater induction of the type I IFN response than the pathogenic wild-type virus49,85. Although in the case of measles virus this disparity in the IFN response has previously been shown by serological techniques48, expression analysis indicated that the antagonism of the response by the wild-type virus originated at the level of transcription. This early induction of the type I IFN response was also evident in microarray studies examining chimeras of the yellow fever vaccine strain that were devised as attenuated live-virus vaccines against other flaviviruses such as Dengue virus87. This contrasted with the low-level induction of type I IFNs by Dengue virus infection as seen by expression profiling using infection of primary cells or macaque disease models87,88.

It is interesting to note that the measles and yellow fever vaccine strains are attenuated by passage in cells from other species. Therefore, with suitable molecular understanding, the ability of some viruses to induce type I IFNs might be optimized by directed molecular techniques, as was done for the truncated-NS1 influenza virus strain. As an alternative, one might consider using recombinant type I IFNs as vaccine adjuvants instead of inducing them with the vaccine constituents86, but at our present level of understanding, these approaches have yet to prove clinically tenable80.

Functional genomics for the evaluation of immunological memory. Functional genomic studies have been more equivocal in assessing the significance of type I IFN production during the immunological memory response. In the aforementioned macaque influenza virus study, animals receiving the attenuated live-virus vaccine showed upregulation of type I IFN pathways in tracheobronchial cells 2 days after challenge, and this coincided with the development of a strong memory response35. This type I IFN induction seems to be weaker than that observed at the corresponding time after the primary exposure to the vaccine, but is far lower than the type I IFN induction observed after challenge of animals receiving the killed-virus vaccine or of naïve animals. This would suggest some role of this innate pathway in stimulating immunological recall.

In contrast to this, examination of transcriptional profiles observed shortly after rechallenge of human PBMCs from individuals previously immunized against influenza virus are more in accord with early production of IFNγ, possibly arising from antigenic stimulation of memory cells89. Dhiman et al. also did not see evidence of a type I IFN response in a microarray study of whole blood taken from individuals immunized with measles virus after rechallenge with an attenuated live-virus vaccine strain, although genes associated with lymphocyte activation and survival were upregulated92. It could be considered that technical issues might hamper the relevance of these studies in assessing the role of type I IFNs in the memory response. In the case of the first study89, PBMCs are not a primary target of influenza virus, so virus internalization might have been inefficient and a type I IFN response might have been poor. In the measles study92, the earliest time point examined was 7 days after rechallenge rather than early, when the type I IFN response would be expected to be strongest. Therefore, further functional genomic experiments, with appropriately designed models, are required to address whether an early innate immune response is a key stage in triggering immunological memory.

Future prospects
Functional genomics has proven to be a highly efficient method for providing broad views of the host response in studies of virus–host interactions. As we have discussed, these techniques have revealed the activation or
MicroRNAs
Single-stranded RNA molecules approximately 21–23 nucleotides in length that are thought to regulate the expression of other genes.

Expression quantitative trait loci mapping (eQTL mapping). Combination of QTL regions of DNA that are closely linked to a phenotypic outcome) mapping and gene-expression analysis to study the genetic basis of gene expression and, by extension, biological regulation.

The repression of innate immune signalling pathways, cross-talk between pathways, the timing and magnitude of the immune response and, depending on the experimental system, the degree to which the immune response varies among individuals.

Conversely, functional genomics has been less effective in pinpointing the role of specific host genes in the antiviral response or, somewhat surprisingly, in identifying previously undiscovered genes and pathways that are important in the infection process, despite this being one of its early goals. Indeed, the early assumption that functional genomics would provide quick answers to the complexities of virus–host interactions has proved naive. How then can greater benefits be gained from using functional genomics to study virus–host interactions? Rather than being used as a singular approach, the future of functional genomics in virology will be in the integration of genomic data with data derived from other high-throughput technologies (FIG. 4).

The obvious complementary approach to functional genomics is proteomics, which will provide much needed information regarding the correlation of gene expression with protein abundance. Our group has begun to integrate genomic and proteomic data to better understand the host response to influenza virus infection. Other possibilities for data integration are also beginning to unfold. For example, microRNAs, which regulate both transcription and translation, might have an important role in mediating virus–host interactions. The discovery of microRNAs in certain large DNA viruses, such as herpesvirus, suggests that some viruses may encode microRNAs to regulate cellular functions. In addition, immunomic strategies will provide additional opportunities to interrogate the host immune response; screens using small interfering RNAs are currently being combined with genomic data to identify specific cellular proteins that are used by viruses during infection. Together with virology, clinical and pathology data, this integrated set of information might provide the systems-biology view that will be needed to clearly understand the role of specific host genes and pathways involved in the development of immunity or disease after virus infection.

Another use for genomics that will no doubt expand is expression quantitative trait loci (eQTL) mapping. The combination of global gene-expression data with eQTL mapping provides greater power in elucidating complex genetic traits in addition to providing insights into specific genes or mutations that might be responsible for the trait in question. This approach is currently being used to better understand the genetic basis for various disease conditions in mice, and it is likely that it will also be useful in increasing our understanding of virus–host interactions. For example, using recombinant inbred strains of mice derived from parental strains that react differently to infection with a given virus, it should be possible to use eQTL mapping to determine chromosomal locations for potential trait-contributing factors and highlight genes of interest for the trait.

With this increased level of complexity, however, it will be important to work closely with the bioinformatics and computational-modelling communities, and to make best use of the sophisticated bioinformatics tools, data-mining schemes and mathematical-modelling strategies that are continually being developed. It might also be necessary to take a step back to simpler experimental systems (such as cell-culture models) to dissect cellular events before moving on to more complex in vivo models. The use of combined computational approaches that can account for gene-regulatory networks and cell-to-cell interactions will also facilitate the move to whole animal physiological modelling.

Functional genomics is clearly providing advances in our understanding of virus–host interactions, and the evolution to an integrated systems-biology approach holds even greater promise for the field. In addition to providing new insights into viral pathogenesis and host immunity, this approach provides a host-oriented antiviral discovery paradigm with the potential for discovering...
new targets for broad-spectrum antiviral therapies\(^ {19}\) and for improving vaccine evaluation and design. We are optimistic about continuing advancements in the technologies and computational methods used to study virus-host interactions and in improved capabilities to identify, characterize and circumvent the strategies used by viruses to outsmart their long-suffering hosts.

\[ \text{Note added in proof} \]
Recent studies have shown that RIG-I preferentially recognizes single-stranded RNA (ssRNA) with polyU motifs, whereas MDA5 recognizes long dsRNA molecules. These differences might help to explain the differential recognition and innate immune signaling induced by different RNA viruses\(^ {17-19} \).
This is a good review discussing host genotypic response genes in patients with severe acute respiratory syndrome. Atypical innate and adaptive immune responses in influenza A viruses. Acad. Sci. USA 107, 10736–10741 (2002).

Despite a limited technical capacity to measure innate immune signals. Nature Rev. Mol. Cell Biol. 8, 1383–1389 (2007).

The relevance of cytokines for development of protective immunity and rational design of vaccines. Cytokine Growth Factor Rev. 18, 195–207 (2007).

Diaz-Mitoma, F. et al. Transcriptional analysis of human peripheral blood mononuclear cells after influenza A virus infection. J. Immunol. 181, 100–112 (2004).

Dhiman, N. et al. Immune activation at effector and gene expression levels after measles vaccination in healthy infants: a pilot study. Hum. Immunol. 66, 1125–1136 (2005).

Wallace, J. C., Korth, M. J., Diamond, D. L., Proll, S. C. & Katze, M. G. Use of genetic and gene expression data: application to phenotypes. Hum. Mol. Genet. 16, 339–353 (2006).

Deu, T. et al. The model organism as a tool for the study of complex traits. Trends Genet. 24, 195–207 (2008).

Kato, H. et al. The length-dependent recognition of nucleic acids by RNA-binding proteins. Trends Genet. 24, 195–207 (2008).

Fusarium, A. Host-cell interaction of attenuated live vaccines. J. Immunol. 176, 1457–1467 (2002).

Boll, J., Berg, K. & Blixen-Kesper, M. M. Viral vectors are induced by innate immune system responses. J. Virol. 78, 1157–1165 (2004).

Despite a limited functional capacity to measure only 1,176 genes, this early paper is a good demonstration of the power of global transcriptional profiling: the results presaged public health service. Nature Rev. Mol. Cell Biol. 8, 1383–1389 (2007).

Diamond et al. Microarray profiling of antiviral antibodies for the development of diagnostics, vaccines, and therapeutics. Clin. Immunol. 111, 201–204 (2005).

Neumann de Vegh, H. E. & Robinson, W. H. Microarray profiling of antiviral antibodies for the development of diagnostics, vaccines, and therapeutics. Clin. Immunol. 111, 201–204 (2005).

Takahashi, K. et al. Nonspecific RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune response. Mol. Cell 29, 425–437 (2007).

Saito, T., Owen, D. M., Denning, D. W., Marcotrigiano, J. & Gale, M. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus. Nature 416, 615–620 (2002).

Neumann de Vegh, H. E. & Robinson, W. H. Microarray profiling of antiviral antibodies for the development of diagnostics, vaccines, and therapeutics. Clin. Immunol. 111, 201–204 (2005).

Takahashi, K. et al. Nonspecific RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune response. Mol. Cell 29, 425–437 (2007).

Saito, T., Owen, D. M., Denning, D. W., Marcotrigiano, J. & Gale, M. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus. Nature 416, 615–620 (2002).

Neumann de Vegh, H. E. & Robinson, W. H. Microarray profiling of antiviral antibodies for the development of diagnostics, vaccines, and therapeutics. Clin. Immunol. 111, 201–204 (2005).

Takahashi, K. et al. Nonspecific RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune response. Mol. Cell 29, 425–437 (2007).

Saito, T., Owen, D. M., Denning, D. W., Marcotrigiano, J. & Gale, M. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus. Nature 416, 615–620 (2002).

Neumann de Vegh, H. E. & Robinson, W. H. Microarray profiling of antiviral antibodies for the development of diagnostics, vaccines, and therapeutics. Clin. Immunol. 111, 201–204 (2005).

Takahashi, K. et al. Nonspecific RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune response. Mol. Cell 29, 425–437 (2007).

Saito, T., Owen, D. M., Denning, D. W., Marcotrigiano, J. & Gale, M. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus. Nature 416, 615–620 (2002).

Neumann de Vegh, H. E. & Robinson, W. H. Microarray profiling of antiviral antibodies for the development of diagnostics, vaccines, and therapeutics. Clin. Immunol. 111, 201–204 (2005).

Takahashi, K. et al. Nonspecific RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune response. Mol. Cell 29, 425–437 (2007).

Saito, T., Owen, D. M., Denning, D. W., Marcotrigiano, J. & Gale, M. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus. Nature 416, 615–620 (2002).

Neumann de Vegh, H. E. & Robinson, W. H. Microarray profiling of antiviral antibodies for the development of diagnostics, vaccines, and therapeutics. Clin. Immunol. 111, 201–204 (2005).

Takahashi, K. et al. Nonspecific RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune response. Mol. Cell 29, 425–437 (2007).

Saito, T., Owen, D. M., Denning, D. W., Marcotrigiano, J. & Gale, M. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus. Nature 416, 615–620 (2002).

Neumann de Vegh, H. E. & Robinson, W. H. Microarray profiling of antiviral antibodies for the development of diagnostics, vaccines, and therapeutics. Clin. Immunol. 111, 201–204 (2005).

Takahashi, K. et al. Nonspecific RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune response. Mol. Cell 29, 425–437 (2007).

Saito, T., Owen, D. M., Denning, D. W., Marcotrigiano, J. & Gale, M. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus. Nature 416, 615–620 (2002).

Neumann de Vegh, H. E. & Robinson, W. H. Microarray profiling of antiviral antibodies for the development of diagnostics, vaccines, and therapeutics. Clin. Immunol. 111, 201–204 (2005).

Takahashi, K. et al. Nonspecific RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune response. Mol. Cell 29, 425–437 (2007).

Saito, T., Owen, D. M., Denning, D. W., Marcotrigiano, J. & Gale, M. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus. Nature 416, 615–620 (2002).

Neumann de Vegh, H. E. & Robinson, W. H. Microarray profiling of antiviral antibodies for the development of diagnostics, vaccines, and therapeutics. Clin. Immunol. 111, 201–204 (2005).

Takahashi, K. et al. Nonspecific RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune response. Mol. Cell 29, 425–437 (2007).

Saito, T., Owen, D. M., Denning, D. W., Marcotrigiano, J. & Gale, M. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus. Nature 416, 615–620 (2002).

Neumann de Vegh, H. E. & Robinson, W. H. Microarray profiling of antiviral antibodies for the development of diagnostics, vaccines, and therapeutics. Clin. Immunol. 111, 201–204 (2005).

Takahashi, K. et al. Nonspecific RNA-sensing mechanism of RIG-I helicase and activation of antiviral immune response. Mol. Cell 29, 425–437 (2007).

Saito, T., Owen, D. M., Denning, D. W., Marcotrigiano, J. & Gale, M. Innate immunity induced by composition-dependent RIG-I recognition of hepatitis C virus. Nature 416, 615–620 (2002).